C.R. Bard and Proseed agree to pay $48.2 million settlement
C.R. Bard Inc., a multinational medical device company, agreed to pay the federal government $48.2 million to settle this whistleblower lawsuit that alleged its urological division and wholly owned subsidiary, ProSeed Inc., paid doctors and hospitals kickbacks to entice them to order Bard’s products at inflated prices to treat Medicare patients with prostate cancer. The W&G whistleblower in the Bard case provided hundreds of documents that proved that Bard was involved in an illegal pay for play scheme.